of (1) to (10), which further comprises boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof.

(12) The pharmaceutical composition according to any one of (1) to (11), which does not comprise sorbic acid.

(13) The pharmaceutical composition according to any one of (1) to (12), which is filled into a container made of polyethylene.

(14) The pharmaceutical composition according to any one of (1) to (13), for prevention or treatment of glaucoma or ocular hypertension, or for reduction of intraocular pressure.

(15) A method for stabilizing isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof by allowing a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof to comprise polyoxyethylene castor oil.

The respective structures of the above-mentioned (1) to (15) can be combined by optionally selecting two or more structures therefrom.

Summary

In an aspect, there is provided a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and polyoxyethylene castor oil, wherein the content of the polyoxyethylene castor oil is

in a range of 2/0.03 to 5,000 parts by mass relative to 1 part by mass of isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.

In another aspect, there is provided a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and polyoxyethylene castor oil, and edetic acid or a salt thereof, and boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof, and glycerol, and water, wherein the pharmaceutical composition does not comprise sorbic acid, the polyoxyethylene castor oil includes polyoxyl 35 castor oil, the content of the polyoxyethylene castor oil is 0.8 to 2% (w/v) in the pharmaceutical composition, and the content of the polyoxyethylene castor oil is in a range of 200 to 2,000 parts by mass relative to 1 part by mass of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.

In another aspect, there is provided a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and polyoxyethylene castor oil, and edetic acid or a salt thereof, and boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof, and glycerol, and sodium hydroxide and/or

hydrochloric acid, and water, wherein the pharmaceutical composition does not comprise sorbic acid, the polyoxyethylene castor oil includes polyoxyl 35 castor oil, the content of the polyoxyethylene castor oil is 0.8 to 2% (w/v) in the pharmaceutical composition, and the content of the polyoxyethylene castor oil is in a range of 200 to 2,000 parts by mass relative to 1 part by mass of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate or a salt thereof.

In another aspect, there is provided a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and polyoxyethylene castor oil, and edetic acid or a salt thereof, and boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof, and glycerol, and benzalkonium chloride, and water, wherein the pharmaceutical composition does not comprise sorbic acid, the polyoxyethylene castor oil includes polyoxyl 35 castor oil, the content of the polyoxyethylene castor oil is 0.8 to 2% (w/v) in the pharmaceutical composition, and the content of the polyoxyethylene castor oil is in a range of 200 to 2,000 parts by mass relative to 1 part by mass of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.

In another aspect, there is provided a pharmaceutical

composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and polyoxyethylene castor oil, and edetic acid or a salt thereof, and boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof, and glycerol, and benzalkonium chloride, and sodium hydroxide and/or hydrochloric acid, and water, wherein the pharmaceutical composition does not comprise sorbic acid, the polyoxyethylene castor oil includes polyoxyl 35 castor oil, the content of the polyoxyethylene castor oil is 0.8 to 2% (w/v) in the pharmaceutical composition, and the content of the polyoxyethylene castor oil is in a range of 200 to 2,000 parts by mass relative to 1 part by mass of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.

In another aspect, there is provided the pharmaceutical composition disclosed herein, for prevention or treatment of glaucoma or ocular hypertension, or for reduction of intraocular pressure.

In another aspect, there is provided a method for stabilizing isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof by allowing a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof to comprise polyoxyethylene castor oil in a range of

2/0.03 to 5,000 parts by mass relative to 1 part by mass of isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.

In another aspect, there is provided a method for producing a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, wherein the method comprises the step of blending polyoxyethylene castor oil in a range of 2/0.03 to 5,000 parts by mass relative to 1 part by mass of isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.

Effects of the Invention

According to the present invention, it is possible to provide a pharmaceutical composition in which the present compound in the pharmaceutical composition is stabilized over a long period of time. The pharmaceutical composition of the present invention has enough safety as a pharmaceutical

CLAIMS

1. A pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and polyoxyethylene castor oil.

2. The pharmaceutical composition according to claim 1, wherein the polyoxyethylene castor oil includes polyoxyethylene castor oil selected from the group consisting of polyoxyl 5 castor oil, polyoxyl 9 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, and polyoxyl 40 castor oil.

3. The pharmaceutical composition according to claim 2, wherein the polyoxyethylene castor oil includes polyoxyl 35 castor oil.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the content of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof is in a range of 0.0001 to 0.1% (w/v).

5. The pharmaceutical composition according to claim 4, wherein the content of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or

a salt thereof is in a range of 0.001 to 0.003% (w/v).

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the content of the polyoxyethylene castor oil is in a range of 0.001 to 5% (w/v).

7. The pharmaceutical composition according to claim 6, wherein the content of the polyoxyethylene castor oil is in a range of 0.8 to 2% (w/v).

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the content of the polyoxyethylene castor oil is in a range of 1 to 20,000 parts by mass relative to 1 part by mass of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof.

9. The pharmaceutical composition according to claim 8, wherein the content of the polyoxyethylene castor oil is in a range of 200 to 2,000 parts by mass relative to 1 part by mass of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof.

10. The pharmaceutical composition according to any one of claims 1 to 9, which further comprises edetic acid or a salt thereof.

11. The pharmaceutical composition according to any one of claims 1 to 10, which further comprises boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof.

12. The pharmaceutical composition according to any one of claims 1 to 11, which does not comprise sorbic acid.

13. The pharmaceutical composition according to any one of claims 1 to 12, which is filled into a container made of polyethylene.

14. The pharmaceutical composition according to any one of claims 1 to 13, for prevention or treatment of glaucoma or ocular hypertension, or for reduction of intraocular pressure.

15. A method for stabilizing isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof by allowing a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof to comprise polyoxyethylene castor oil.

CLAIMS

1. A pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and polyoxyethylene castor oil,
wherein the content of the polyoxyethylene castor oil is in a range of 2/0.03 to 5,000 parts by mass relative to 1 part by mass of isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.

2. The pharmaceutical composition according to claim 1, wherein the polyoxyethylene castor oil includes polyoxyethylene castor oil selected from the group consisting of polyoxyl 5 castor oil, polyoxyl 9 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, and polyoxyl 40 castor oil.

3. The pharmaceutical composition according to claim 2, wherein the polyoxyethylene castor oil includes polyoxyl 35 castor oil.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the content of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or

a salt thereof is in a range of 0.0001 to 0.1% (w/v).

5. The pharmaceutical composition according to claim 4, wherein the content of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof is in a range of 0.001 to 0.003% (w/v).

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the content of the polyoxyethylene castor oil is in a range of 0.001 to 5% (w/v).

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the content of the polyoxyethylene castor oil is in a range of 0.5 to 3% (w/v).

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the content of the polyoxyethylene castor oil is in a range of 0.8 to 2% (w/v).

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the content of the polyoxyethylene castor oil is in a range of 100 to 3,000 parts by mass relative to 1 part by mass of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof.

10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the content of the polyoxyethylene castor oil is in a range of 200 to 2,000 parts by mass relative to 1 part by mass of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof.

11. The pharmaceutical composition according to any one of claims 1 to 10, which further comprises edetic acid or a salt thereof.

12. The pharmaceutical composition according to any one of claims 1 to 11, which further comprises boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof.

13. The pharmaceutical composition according to any one of claims 1 to 12, which does not comprise sorbic acid.

14. A pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and polyoxyethylene castor oil, and
edetic acid or a salt thereof, and
boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof, and
glycerol, and

water,

wherein the pharmaceutical composition does not comprise sorbic acid,

the polyoxyethylene castor oil includes polyoxyl 35 castor oil,

the content of the polyoxyethylene castor oil is 0.8 to 2% (w/v) in the pharmaceutical composition, and

the content of the polyoxyethylene castor oil is in a range of 200 to 2,000 parts by mass relative to 1 part by mass of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.

15. A pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and

polyoxyethylene castor oil, and

edetic acid or a salt thereof, and

boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof, and

glycerol, and

sodium hydroxide and/or hydrochloric acid, and

water,

wherein the pharmaceutical composition does not comprise sorbic acid,

the polyoxyethylene castor oil includes polyoxyl 35 castor

oil,

the content of the polyoxyethylene castor oil is 0.8 to 2% (w/v) in the pharmaceutical composition, and

the content of the polyoxyethylene castor oil is in a range of 200 to 2,000 parts by mass relative to 1 part by mass of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate or a salt thereof.

16. A pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and

polyoxyethylene castor oil, and

edetic acid or a salt thereof, and

boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof, and

glycerol, and

benzalkonium chloride, and

water,

wherein the pharmaceutical composition does not comprise sorbic acid,

the polyoxyethylene castor oil includes polyoxyl 35 castor oil,

the content of the polyoxyethylene castor oil is 0.8 to 2% (w/v) in the pharmaceutical composition, and

the content of the polyoxyethylene castor oil is in a range of

200 to 2,000 parts by mass relative to 1 part by mass of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.

17. A pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and
polyoxyethylene castor oil, and
edetic acid or a salt thereof, and
boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof, and
glycerol, and
benzalkonium chloride, and
sodium hydroxide and/or hydrochloric acid, and
water,
wherein the pharmaceutical composition does not comprise sorbic acid,
the polyoxyethylene castor oil includes polyoxyl 35 castor oil,
the content of the polyoxyethylene castor oil is 0.8 to 2% (w/v) in the pharmaceutical composition, and
the content of the polyoxyethylene castor oil is in a range of 200 to 2,000 parts by mass relative to 1 part by mass of the isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt

thereof.

18. The pharmaceutical composition according to any one of claims 1 to 17, which is filled into a container made of polyethylene.

19. The pharmaceutical composition according to any one of claims 1 to 18, for prevention or treatment of glaucoma or ocular hypertension, or for reduction of intraocular pressure.

20. A method for stabilizing isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof by allowing a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof to comprise polyoxyethylene castor oil in a range of 2/0.03 to 5,000 parts by mass relative to 1 part by mass of isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.

21. A method for producing a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof,
wherein the method comprises the step of blending polyoxyethylene castor oil in a range of 2/0.03 to 5,000 parts

by mass relative to 1 part by mass of isopropyl 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof.